A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study
about
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study
description
scientific article published on 19 February 2011
@en
name
A multicentre dose-escalating ...... treatment: a phase I/II study
@en
type
label
A multicentre dose-escalating ...... treatment: a phase I/II study
@en
prefLabel
A multicentre dose-escalating ...... treatment: a phase I/II study
@en
P2093
P1476
A multicentre dose-escalating ...... treatment: a phase I/II study
@en
P2093
C Villanueva
E Magherini
J P Machiels
P304
P356
10.1016/J.EJCA.2011.01.001
P50
P577
2011-02-19T00:00:00Z